HK1250752A1 - 治療骨髓增生性障礙的方法 - Google Patents
治療骨髓增生性障礙的方法Info
- Publication number
- HK1250752A1 HK1250752A1 HK18110217.6A HK18110217A HK1250752A1 HK 1250752 A1 HK1250752 A1 HK 1250752A1 HK 18110217 A HK18110217 A HK 18110217A HK 1250752 A1 HK1250752 A1 HK 1250752A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- myeloproliferative disorders
- treating myeloproliferative
- treating
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1716—Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/202—IL-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562148005P | 2015-04-15 | 2015-04-15 | |
US201562218869P | 2015-09-15 | 2015-09-15 | |
PCT/US2016/027773 WO2016168612A1 (en) | 2015-04-15 | 2016-04-15 | Methods for treating myeloproliferative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1250752A1 true HK1250752A1 (zh) | 2019-01-11 |
Family
ID=57127338
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18110217.6A HK1250752A1 (zh) | 2015-04-15 | 2018-08-09 | 治療骨髓增生性障礙的方法 |
HK18115088.1A HK1256036A1 (zh) | 2015-04-15 | 2018-11-26 | 治療骨髓增生性障礙的方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18115088.1A HK1256036A1 (zh) | 2015-04-15 | 2018-11-26 | 治療骨髓增生性障礙的方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20180318303A1 (zh) |
EP (1) | EP3283655A4 (zh) |
JP (1) | JP2018512164A (zh) |
CN (1) | CN108138234A (zh) |
AU (1) | AU2016248317A1 (zh) |
CA (1) | CA2983004A1 (zh) |
HK (2) | HK1250752A1 (zh) |
RU (1) | RU2017139122A (zh) |
WO (1) | WO2016168612A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014331954B2 (en) | 2013-10-08 | 2020-05-21 | Promedior, Inc. | Methods for treating fibrotic cancers |
JP6852397B2 (ja) | 2016-12-28 | 2021-03-31 | 株式会社島津製作所 | 分析用試料の調製方法および分析方法 |
JP7300394B2 (ja) | 2017-01-17 | 2023-06-29 | ヘパリジェニックス ゲーエムベーハー | 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害 |
EP3589750B1 (en) * | 2017-03-01 | 2022-05-04 | The Board of Trustees of the Leland Stanford Junior University | Highly specific circular proximity ligation assay |
DE102017107661A1 (de) * | 2017-04-10 | 2018-10-11 | Universität Rostock | SH2B-Adapterprotein-3 für die Vorhersage einer Knochenmarkantwort und Immunantwort |
BR112021001204A2 (pt) * | 2018-07-31 | 2021-04-27 | Geron Corporation | métodos de identificação de pacientes que provavelmente se beneficiarão do tratamento com um inibidor de telomerase |
KR101962869B1 (ko) * | 2018-08-02 | 2019-03-27 | 주식회사 우리메디칼 | 이미지 분석에 기반한 골수판독 지원 장치 |
AU2019370284A1 (en) * | 2018-10-31 | 2021-04-22 | Stemline Therapeutics, Inc. | Combination therapy method of treating myeloproliferative neoplasms with a diphtheria toxin-human interleukin-3 conjugate in combination with other agents |
AU2020232597A1 (en) | 2019-03-01 | 2021-08-19 | Allogene Therapeutics, Inc. | Constitutively active chimeric cytokine receptors |
US11786553B2 (en) | 2019-03-01 | 2023-10-17 | Allogene Therapeuctics, Inc. | Chimeric cytokine receptors bearing a PD-1 ectodomain |
CN111426850B (zh) * | 2020-01-15 | 2021-12-21 | 上海众启生物科技有限公司 | 用于阿尔茨海默症自身抗体检测的含dnajc8蛋白片段的组合物 |
KR20220145846A (ko) | 2020-02-24 | 2022-10-31 | 알로젠 테라퓨틱스 인코포레이티드 | 향상된 활성을 갖는 bcma car-t 세포 |
EP3900789A1 (en) | 2020-04-23 | 2021-10-27 | Universitätsklinikum Jena | Pharmaceutical combination for the treatment of myeloproliferative neoplasms |
CN113549597B (zh) * | 2021-07-22 | 2022-03-25 | 浙江大学 | 一种人原发性骨髓纤维化细胞株及其应用 |
CN114752575B (zh) * | 2022-04-07 | 2023-06-13 | 内蒙古工业大学 | 一种nad+依赖性脱氢酶基因及其在提高辅酶q10产量中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2877013A1 (fr) * | 2004-10-27 | 2006-04-28 | Assist Publ Hopitaux De Paris | Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez |
US8329659B2 (en) * | 2009-06-17 | 2012-12-11 | Promedior, Inc. | SAP variants and their use |
AU2014331954B2 (en) * | 2013-10-08 | 2020-05-21 | Promedior, Inc. | Methods for treating fibrotic cancers |
-
2016
- 2016-04-15 WO PCT/US2016/027773 patent/WO2016168612A1/en active Application Filing
- 2016-04-15 JP JP2017554345A patent/JP2018512164A/ja active Pending
- 2016-04-15 AU AU2016248317A patent/AU2016248317A1/en not_active Abandoned
- 2016-04-15 US US15/566,692 patent/US20180318303A1/en not_active Abandoned
- 2016-04-15 CN CN201680034923.6A patent/CN108138234A/zh active Pending
- 2016-04-15 RU RU2017139122A patent/RU2017139122A/ru unknown
- 2016-04-15 EP EP16780843.5A patent/EP3283655A4/en not_active Withdrawn
- 2016-04-15 CA CA2983004A patent/CA2983004A1/en not_active Abandoned
-
2018
- 2018-08-09 HK HK18110217.6A patent/HK1250752A1/zh unknown
- 2018-11-26 HK HK18115088.1A patent/HK1256036A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
RU2017139122A3 (zh) | 2019-08-28 |
US20180318303A1 (en) | 2018-11-08 |
AU2016248317A1 (en) | 2017-11-09 |
CN108138234A (zh) | 2018-06-08 |
EP3283655A1 (en) | 2018-02-21 |
CA2983004A1 (en) | 2016-10-20 |
JP2018512164A (ja) | 2018-05-17 |
EP3283655A4 (en) | 2018-12-05 |
WO2016168612A1 (en) | 2016-10-20 |
RU2017139122A (ru) | 2019-05-15 |
HK1256036A1 (zh) | 2019-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1259336A1 (zh) | 用於治療骨髓增生性病症的方法 | |
HK1256036A1 (zh) | 治療骨髓增生性障礙的方法 | |
HK1252741A1 (zh) | 用於治療神經疾病的組合物和方法 | |
IL285151A (en) | Methods for the treatment of fgf21-related disorders | |
ZA201705673B (en) | Methods for treating skin | |
IL279308A (en) | Methods for the treatment of heptidine-mediated disorders | |
EP3380121A4 (en) | METHOD FOR THE TREATMENT OF EYE DISEASES | |
HK1244217A1 (zh) | 用於治療蛋白質病的方法 | |
IL250715A0 (en) | Preparations and methods for the treatment of cultural disorders | |
PT3119911T (pt) | Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+ | |
IL247699A0 (en) | Preparations and methods for the treatment of kidney disorders | |
EP3166610A4 (en) | Methods for treating neurologic disorders | |
HK1252996A1 (zh) | 用於治療癲癇的方法 | |
HK1251965A1 (zh) | 用於治療癲癇的方法 | |
HK1248133A1 (zh) | 治療神經母細胞瘤的方法 | |
HK1245127A1 (zh) | 治療腦疾病的方法和組合物 | |
EP3262065C0 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSTROGLYCANOPATHY DISEASES | |
IL254336A0 (en) | A new treatment method | |
HK1256371A1 (zh) | 用於治療腫瘤的方法 | |
GB201602011D0 (en) | Treating skin disorders | |
GB201517995D0 (en) | Products for treating psychogenic pain disorders | |
GB201513993D0 (en) | Methods for the treatment of inflammatory disorders | |
GB201513345D0 (en) | Methods for the treatment of Inflammatory disorders | |
GB201413532D0 (en) | Combination therapy for treating hearing disorders | |
GB201507113D0 (en) | Methods for the treatment of inflammatory disorders |